<DOC>
	<DOCNO>NCT02273167</DOCNO>
	<brief_summary>This study evaluate efficacy , safety tolerability NER1006 compare MOVIPREP adult patient require bowel cleanse prior procedure require clean bowel , use 2-Day Split-Dosing 1-Day Morning Split-Dosing regimen . Approximately 810 patient randomised aim achieve minimum 245 patient 3 group .</brief_summary>
	<brief_title>Multicenter Randomized Parallel Group Phase III Study Comparing Bowel Cleansing Efficacy , Safety Tolerability NER1006 Versus MOVIPREP® Using 2-Day Split-Dosing 1-Day Morning Split-Dosing Regimens Adults .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Patients must provide write informed consent . Male female outpatient inpatient age : ≥18 ≤85 year undergo screening , surveillance diagnostic colonoscopy . Females childbearing potential must negative pregnancy test Screening must practise one follow method birth control agree continue regimen throughout study period ( unless postmenopausal surgically sterile ) : Oral , contraceptive ( minimum three month study entry ) combination condom ; Intrauterine device combination condom ; Double barrier method ( condom , sponge diaphragm , vaginal ring spermicidal gel cream . Willing able complete entire study comply instruction . Patients past history within last 12 month current episode severe constipation ( require repeat use laxatives/enema physical intervention resolution ) , know suspected ileus , gastrointestinal obstruction , gastric retention , bowel perforation , toxic colitis megacolon . Patients ongoing severe acute Inflammatory Bowel Disease . Patients previous significant gastrointestinal surgery , include colonic resection , subtotal colectomy , abdominoperineal resection , defunctioning colostomy , Hartmann 's procedure defunctioning ileostomy similar surgery involve structure function small large colon . Regular use laxatives colon motility alter drug last month ( i.e . 23 time per week ) and/or laxative use within 72 hour prior administration preparation . Patients active intestinal bleeding episode clinically significant low hemoglobin level &lt; 9 g/dL woman &lt; 11 g/dL men screen . Known glucose6phosphate dehydrogenase ( G6PD ) deficiency . Known phenylketonuria . Known hypersensitivity polyethylene glycol , ascorbic acid sulfate Past history within last 12 month evidence ongoing clinically relevant electrocardiogram ( ECG ) abnormality ( e.g . arrhythmia ) . History uncontrolled hypertension systolic blood pressure &gt; 170 mmHg diastolic blood pressure &gt; 100 mmHg . Patients cardiac insufficiency NYHA grade III IV . Patients severe renal insufficiency ( i.e . GFR , &lt; 30 mL/min/1.73m2 ) . Patient serum albumin &lt; 3.4 g/dL . Patients liver disease grade B C accord Child Pugh classification . Patients suffer dehydration screen evaluate Investigator physical examination laboratory investigation . Patients clinically significant electrolyte abnormality , whether preexist note screening , hypernatremia , hyponatremia , hyperphosphatemia , hypermagnesemia , hypokalemia , hypocalcaemia dehydration , secondary use diuretic angiotensin convert enzyme ( ACE ) inhibitor . Patients clinically significant hematological parameter include coagulation profile screen . Patients impaired consciousness might predispose pulmonary aspiration . Patients undergo colonoscopy foreign body removal and/or decompression . Patients pregnant lactating , intend become pregnant study . Clinically relevant finding physical examination base Investigator 's judgment . History drug alcohol abuse within 12 month prior dose . Concurrent participation investigational drug device study participation within three month study entry . Patients order live institution court authority order</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>